Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
January-2027 Volume 33 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-2027 Volume 33 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML

  • Supplementary Files
    • Supplementary_Data.pdf
Review Open Access

Residual gastric cancer risk after Helicobacter pylori eradication: Mucosal immune trajectories (Review)

  • Authors:
    • Jian Chen
    • Bolin Tang
    • Li Zhou
  • View Affiliations / Copyright

    Affiliations: Department of Laboratory Medicine, People's Hospital of Yuxi City, Yuxi, Yunnan 653100, P.R. China, School of Public Health, Dali University, Dali, Yunnan 671000, P.R. China
    Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 5
    |
    Published online on: November 6, 2026
       https://doi.org/10.3892/ol.2026.15940
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:


Abstract

Helicobacter pylori is the leading modifiable cause of noncardia gastric cancer. Eradication lowers the incidence of primary and metachronous gastric neoplasia, yet a clinically meaningful risk remains once extensive atrophy, intestinal metaplasia or dysplasia is established. Current surveillance incorporates infection status and structural disease burden but does not directly assess biological recovery of the gastric mucosa. The present review examined whether mucosal immune trajectories after eradication are heterogeneous and whether localized immune measurements could explain variation in residual risk beyond morphology and epithelial‑field alterations. Single‑cell and spatial studies of human tissue have identified infection‑ and precursor‑associated changes in myeloid differentiation, antigen presentation, T‑cell states, metaplastic epithelium and stroma. Longitudinal evidence is less developed. Selected mucosal T‑cell measurements support reversibility of specific responses, whereas gene‑expression, histologic and microbiome trajectories provide molecular, structural or contextual evidence. Outcome‑linked CD8‑associated trajectories provide the closest currently available clinical‑outcome immune evidence, but remain non‑functional proxies derived from a post‑resection population. A 2026 human single‑cell study further identified persistent stromal and immunosuppressive niche features in post‑eradication chronic atrophic gastritis, but did not provide paired longitudinal immune‑function measurements or prospective neoplastic outcomes. Among the studies identified through the present search, none combined confirmation of eradication, paired measurements of immune function, concurrent assessment of the epithelial field and prospective dysplasia or cancer outcomes in individuals without previous gastric neoplasia. Therefore, the available evidence supports heterogeneous tissue recovery rather than a validated persistent immune state. Clinical translation would require reproducible functional immune activity, or a functionally validated proxy, together with independent outcome association, external validation and a clinically meaningful improvement in surveillance decisions beyond established histologic staging and lesion extent. Until such evidence is available, candidate immune markers should remain research tools and should not modify guideline‑based surveillance.

Introduction

Gastric cancer remains a major global health burden and a leading cause of cancer-related mortality, with a disproportionate incidence in East Asia and in selected regions of Latin America and Eastern Europe (1,2). Helicobacter pylori (H. pylori) is the predominant infectious cause of noncardia gastric cancer (3–8). The Correa cascade describes progression from chronic active gastritis through atrophy, gastric intestinal metaplasia and dysplasia to invasive adenocarcinoma (6,7,9,10). Although this sequence remains clinically useful, it also exposes an important prevention gap, whereby current guidelines and syntheses of eradication studies distinguish microbiological cure from elimination of residual neoplastic risk (11–14). Longitudinal studies further indicate that atrophy may improve after eradication, whereas intestinal metaplasia often persists or regresses only minimally over time (15,16). Therefore, clearance of the organism may precede, but does not ensure, restoration of a biologically equivalent gastric mucosa.

Eradication remains the cornerstone of gastric cancer prevention. The Maastricht VI/Florence consensus emphasizes that preventive benefit is greatest before advanced atrophy or intestinal metaplasia has developed (11). Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III) incorporates high-quality endoscopy, image enhancement, systematic biopsy, Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) staging and surveillance of advanced precursor lesions (12). The 2025 American Gastroenterological Association Clinical Practice Update likewise recommends individualized screening and surveillance according to H. pylori status, family history, demographic risk, endoscopic findings and histology (17), while International Agency for Research on Cancer guidance extends screen-and-treat strategies to population-level prevention (18). These approaches address the initiating exposure and quantify structural risk, but provide limited insight into whether the mucosal tissue state has recovered biologically.

Randomized trials, cohort studies and systematic reviews consistently show lower rates of incident gastric cancer and metachronous neoplasia after eradication (19–23). Earlier meta-analyses questioned the magnitude of benefit once intestinal metaplasia or dysplasia was present (13,24). Nevertheless, a 2025 synthesis of randomized trials reported risk reduction in these groups, although the effect estimates varied by region, duration of follow-up and study quality (14). Therefore, the remaining question is not whether eradication is beneficial, but whether residual risk is fully explained by persistent structural damage or whether additional tissue-level features convey independent information.

Against this background, the present review examined whether post-eradication mucosal immune trajectories add information beyond established measures of structural risk. Specifically, it distinguished candidate immune signals from residual inflammation, metaplastic architecture, epithelial-field alterations and exposure misclassification; separated biological persistence from clinical utility; and defined the longitudinal comparisons needed to support or refute the hypothesis.

The starting premise is that H. pylori eradication reduces the risk of primary and metachronous gastric neoplasia (19–23), although effect estimates in established intestinal metaplasia or dysplasia differ across syntheses (13,14,24) and metaplastic tissue may persist (15,16). The working hypothesis is that a subset of eradicated patients may retain localized immune abnormalities that are not explained by active inflammation, morphologic burden or epithelial-field alterations. Such a signal would need to recur in anatomically matched samples, show functional relevance and retain information after competing tissue variables have been considered. Otherwise, it is more appropriately interpreted as residual infection-associated remodeling rather than a distinct clinically informative state.

Literature search and evidence appraisal

Literature identification

The present concept-driven narrative review evaluated a falsifiable translational proposition rather than estimating a pooled effect. Searches were updated through 1 July 2026 in PubMed/MEDLINE (https://pubmed.ncbi.nlm.nih.gov/) and supplemented by Web of Science Core Collection (https://pubmed.ncbi.nlm.nih.gov/) searches and forward and backward citation tracking. Search blocks covered H. pylori exposure and eradication; gastric atrophy, intestinal metaplasia, dysplasia and metachronous neoplasia; local immune responses, including tissue-resident memory T-cell (TRM) biology; single-cell and spatial methods; post-eradication tissue trajectories; and recent reviews of residual risk, oncogenic signaling and gastric immune tolerance. Study selection prioritized relevance to human gastric mucosa, longitudinal or paired designs, directness to the proposition under evaluation and explicit measurement of competing structural or epithelial fields. Animal models, organoids, established gastric cancer and other tumor types were included only as indirect mechanistic or methodological precedents.

No restriction was placed on the start date, and only English-language reports were considered. Foundational studies were retained when they established staging systems, pathogenetic concepts or metaplastic biology. As the present review was concept driven, no pooled effect estimate was calculated, and no formal risk-of-bias instrument was applied. Instead, each major inference was classified by disease stage, study design, population relevance, directness of evidence and the specific proposition it could support. Evidence was downgraded when it relied on cross-sectional sampling, post-resection populations, unvalidated proxies or mechanistic analogy. Table SI reports the search framework and selection principles, and Table SII provides a study-level appraisal of the directness and limitations of the evidence.

Evidence hierarchy and interpretive limits

The evidence base falls into the following four categories: i) Trials, cohorts and systematic reviews establish the residual-risk premise, with eradication reducing, but not eliminating, gastric cancer risk; ii) human tissue studies in gastritis, atrophy, intestinal metaplasia or dysplasia characterize remodeling associated with infection and precursor lesions; iii) paired post-eradication studies provide the most direct evidence of reversibility or persistence; and iv) findings from animals, organoids, established gastric cancer and other tumor types remain mechanistic analogies rather than evidence in gastric precursor tissue.

Evidence was weighted according to its directness to the claim rather than the sophistication of the technology used. Paired functional measurements in human tissue after confirmed eradication provide the strongest evidence for the central hypothesis. Molecular, histologic, microbiome and spatial measurements can reveal discordant recovery but remain contextual evidence or candidate proxies until linked to functional immune activity. Cross-sectional human atlases define states associated with infection or precursor lesions, whereas model systems and studies of established cancers identify mechanisms for subsequent testing. Confirmation would require verified exposure status, paired measurements of immune persistence and function, concurrent assessment of morphology and the epithelial field, and prospective dysplasia or gastric cancer outcomes in the same participants. Among the studies identified through the present search, none incorporated this complete evidentiary chain. Therefore, the available evidence supports infection-associated remodeling and heterogeneous recovery, while a durable, clinically meaningful immune state remains unproven, as summarized in Table I.

Table I.

Current human evidence: Supported vs. unproven.

Table I.

Current human evidence: Supported vs. unproven.

Evidence categorySupportsUnprovenEvidence
Residual-risk premiseEradication reduces risk but does not eliminate it.A specific immune mechanism or clinically useful biomarker.Trials and syntheses of eradicationeffects, including conflicting findings in patients with advanced precursor lesions (13,14,19–24), interpreted alongside current guidelines and structural-risk frameworks (11,12,15–17).
Direct evidence from infected or precursor tissueMeasurable immune, epithelial and spatial heterogeneity during infection or precursor-stage disease.Persistence after eradication or clinical utility. Infection-associated immune differences (61,69); epithelial, spatial and immune-cell heterogeneity across infected mucosa and precursor lesions (62,70–75); gastric TRM biology during H. pylori infection and experimental eradication/reinfection (63,90,91); a resident-memory CD8+ T-cell cluster identified in a single ex vivo human gastric intestinal metaplasia biopsy (64); and clonal and methylation fields within intestinal metaplasia (56,57).
Human evidence relevant to recovery after eradicationReversibility of selected T-cell responses, together with heterogeneous molecular, structural, microbial and stromal recovery; the closest available outcome-linked immune evidence comes from post-resection CD8-associated trajectories.A persistent, functionally defined immune state or a clinically useful immune marker in a primary-prevention population.Functional T-cell reversibility (53); outcome-linked CD8-associated trajectories after prior neoplasia (54); molecular response (76); structural trajectories (15,16); microbiome trajectories (35,36); and direct post-eradication stromal/immune-associated remodeling in chronic atrophic gastritis (55).
Indirect mechanistic evidenceBiological plausibility for myeloid-stromal and immune-epithelial interactions.Direct causality in gastric mucosa containing precursor lesions.Selected studies of gastric cancer and metaplasia models, together with one methodological precedent for spatial analysis (47,48,77,80–82,92–96,106).
Decisive human evidence not yet availablePost-eradication immune persistence and function, independence from morphology and epithelial-field burden, prospective outcome association and added clinical value in the intended prevention population.The current cross-study evidence cannot support this integrated inference.A prospective multicenter paired longitudinal cohort in which all decisive elements are measured in the same participants.

[i] Evidence is graded by directness to the proposition being evaluated rather than by technological sophistication. H. pylori, Helicobacter pylori; TRM, tissue-resident memory T-cell; CD8, cluster of differentiation 8.

Current clinical framework and its limits

Current risk stratification for gastric precursor lesions relies on endoscopic and histologic assessment. OLGA relates the extent and severity of atrophy to gastric cancer risk (25), whereas OLGIM uses intestinal metaplasia as a more reproducible surrogate (26). The updated Sydney System standardizes the grading of inflammation, activity, atrophy, intestinal metaplasia and H. pylori status (27). MAPS II and III translate these measures into surveillance recommendations (12,28), and the Kyoto consensus classifies H. pylori gastritis as both an infectious disease and a precursor condition (29). Prospective surveillance data and endoscopic grading systems further support risk stratification of gastric precursor lesions (30,31), and their continued clinical use reflects their standardization, feasibility and established relevance.

The principal limitation of OLGA, OLGIM and Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) is one of scope, not validity. These systems quantify the extent and distribution of atrophy or intestinal metaplasia, yet patients within the same morphologic category may differ in host susceptibility and dietary exposure (32–34). Infection history and gastric microbial ecology introduce further heterogeneity (8,29,35–39). The relevant issue is whether tissue-level functional measures add risk information after established clinical and structural variables have been accounted for.

H. pylori-driven carcinogenesis extends beyond direct epithelial injury. Adhesion, cytotoxin-associated gene A protein (CagA), vacuolating cytotoxin A (VacA), the cag type IV secretion system, urease activity, inflammatory signaling and disruption of epithelial polarity or β-catenin regulation all contribute to disease progression (6,7,40–46). Experimental and translational studies implicate gastric stem-cell and regenerative programs in injury-associated epithelial remodeling and carcinogenesis (10,47–49), while immune and inflammatory responses further shape the mucosal environment during persistent infection (6,7,50,51). Prospective human evidence also links H. pylori infection to the subsequent development of gastric cancer (52). Therefore, a precursor lesion is best viewed as a dynamically organized tissue system, although epithelial clones and metaplastic architecture may still account for a substantial proportion of residual risk.

A falsifiable tissue-based framework

Biological support: Localization, persistence and function

Post-eradication immune-associated remodeling is used in the present review as a provisional term for anatomically localized immune features detected after confirmed H. pylori eradication (53–55). It does not denote a disease entity, a clinical label or evidence of a causal contribution to residual risk. The epithelial field refers to metaplastic, clonal and epigenetic alterations distributed within mucosa at risk (56–58). For operational purposes, epithelial-field burden should be separated into structural and molecular components. The structural field should be represented, at minimum, by OLGIM stage, the anatomical extent and distribution of intestinal metaplasia assessed by EGGIM or systematically mapped histology, and metaplasia subtype, including the extent or proportion of incomplete-type metaplasia where available (12,26,27,31,57). The molecular epithelial field comprises quantitatively assessed clonal/mutational and/or methylation burden in non-neoplastic mucosa (56,57). As no fixed methylation-marker panel has been validated specifically for post-eradication precursor mucosa (56,57), marker selection should be prespecified and analytically validated rather than defined by an arbitrary numerical minimum (59,60). To qualify as a distinct immune-associated signal, a feature must be linked to previous exposure, localized to precursor-lesion mucosa or its surrounding field, reproducible after active inflammation and reinfection have been excluded, functionally relevant, and not explained by morphologic or epithelial-field burden.

Cell abundance alone cannot establish persistence (55,61,62). More compelling evidence would require recurrence in anatomically matched paired tissue together with measurable functional immune activity, such as altered antigen presentation, myeloid function, T-cell persistence or ex vivo effector capacity (53,61,63,64). Pathway-level and spatial measurements should remain candidate proxies until validated against function (55,60,62).

Epithelial, stromal and microbial measurements provide essential context and competing explanations, but do not in themselves establish immune persistence (35,55–57). The greater the structural burden, the more important it becomes to show that an immune measurement contributes independent information (12,30,59,65).

Clinical relevance: Independent prediction and utility

Clinical relevance requires more than biological persistence. A tissue feature must remain associated with prespecified dysplasia or gastric cancer outcomes after clinical, morphologic, infectious and epithelial-field variables have been considered (12,54,56,57,59,60,65). The association should be replicated in external cohorts, and any improvement in risk stratification or surveillance decisions should provide sufficient clinical benefit to justify additional biopsies, assay costs and the potential harms of misclassification (17,65,66).

Causality and prediction should be evaluated separately. A persistent signal may be biologically genuine yet add little to clinical risk assessment, whereas a useful predictor does not need to be causal. Therefore, Table II distinguishes discovery-stage tissue features from clinically useful markers, which require a parsimonious assay, external validation and demonstrable clinical utility (59,60,65,66).

Table II.

Criteria for biological support and clinical utility.

Table II.

Criteria for biological support and clinical utility.

A, Biological support

Required criterionOperational questionMinimum evidence
Exposure dependenceCan the state be linked to active or previous H. pylori exposure?Documented exposure history combined with tissue measurement (11,17,53,61).
Tissue localizationIs the state localized to gastric mucosa containing a precursor lesion or to its surrounding field?Standardized antrum/corpus mapping with spatial or multiplex assessment (12,26,27,62)
PersistenceIs the feature reproduced at prespecified intervals after confirmed eradication?Standardized paired sampling at empirically justified intervals sufficient to test persistence; no interval should be treated as a biological threshold (16,53,76).
Functional relevanceDoes the feature alter antigen presentation, myeloid activity, T-cell surveillance or tissue organization?A direct functional assay is preferred. Pathway-level or spatial evidence must be validated against functional immune activity; abundance alone is insufficient (53,61,63,91).

B, Clinical utility

Required criterionOperational questionMinimum evidence

Independent outcome associationDoes the feature predict incident dysplasia or gastric cancer after established covariates have been included?Prospective association with prespecified, stage-appropriate outcomes in the population in which persistence and competing tissue fields are measured (12,17,54,59,60,65).
External validation and clinical utilityDoes a prespecified assay remain well calibrated and improve surveillance decisions in independent cohorts?External validation, adequate calibration, transparent reporting and clinically meaningful incremental value, consistent with established biomarker and prediction-model principles (59,60,65,66).

[i] H. pylori, Helicobacter pylori.

Relationship to trained immunity, tissue-resident memory and field effects

Trained immunity, tissue-resident memory and field cancerization describe different forms of biological persistence. Trained immunity refers to durable functional reprogramming of innate cells or their progenitors (67), TRM to antigen-experienced lymphocytes retained within tissue (68), and field cancerization to spatially distributed molecular alterations in epithelium at risk (58). Each provides a plausible precedent for incomplete biological normalization after H. pylori eradication, but none is equivalent to the immune-associated state considered in the present review.

A clinically relevant post-eradication immune signal would need to persist after confirmed eradication, demonstrate functional relevance, and retain outcome information after metaplastic, clonal and methylation fields have been considered. Tissue residence or mechanistic similarity alone is insufficient; these concepts are useful only insofar as they define testable comparisons involving exposure dependence, localization, persistence, function and residual outcome information.

Current evidence and unresolved questions

Recent high-resolution studies have documented infection-associated differences in the human gastric immune ecosystem. A 2025 study combining single-cell RNA sequencing with T-cell receptor analysis compared H. pylori-positive and H. pylori-negative gastric samples and identified reduced antigen presentation and phagocytic programs, altered monocyte-to-macrophage differentiation and attenuated T-cell states in infected tissue (61). A separate multi-omic survey of asymptomatic infection reported coordinated microbial and immune differences (69). These cross-sectional studies establish measurable remodeling during active infection, but neither included paired gastric mucosal biopsies obtained from the same individuals before and after H. pylori eradication.

Single-cell and spatial studies have resolved epithelial lineages, tissue organization and localized cell-cell interactions in gastritis and intestinal metaplasia (62,70–75). Genomic and methylation studies have also identified clonal and epigenetic heterogeneity within intestinal metaplasia (56,57). These datasets generate candidate epithelial-immune relationships, but cannot determine whether an immune-associated feature persists after eradication.

More direct post-eradication tissue evidence has also emerged. A 2026 single-cell study of 22 human gastric antral mucosal samples spanning active infection and post-eradication chronic atrophic gastritis identified persistent immunomodulatory fibroblast states and an immunosuppressive stromal-epithelial niche after eradication (55). This study moves beyond tumor-stage analogy by examining post-eradication precursor mucosa directly. However, its stage-stratified design did not provide anatomically paired longitudinal sampling, direct immune-function assays or prospective neoplastic outcomes.

Post-eradication studies indicate heterogeneous recovery across immune, molecular, structural, microbial, stromal and outcome-linked domains (15,16,35,36,53–55,76). Ihan et al (53) directly measured selected T-cell responses after eradication, whereas Kim et al (54) provided the closest currently available outcome-linked immune evidence through post-resection CD8-associated trajectories. The remaining studies primarily assessed gene expression, histology or microbial composition (15,16,35,36,76). Differences in population, sampling and outcome definition preclude an integrated causal inference. The beginning of section 7 and Table SII provide the study-level appraisal, and Fig. 1 summarizes the competing trajectories.

Competing trajectories of gastric
tissue recovery and residual risk after eradication. The dominant
pathway emphasizes established eradication-associated risk
reduction followed by heterogeneous tissue recovery. Solid arrows
denote directly observed post-eradication changes or established
structural associations; dashed arrows denote candidate or
unresolved relationships that require longitudinal validation.
Dotted connectors indicate baseline pathological modifiers. Studies
(13,14,19–24)
address eradication-associated risk reduction and residual risk.
Overall and metachronous risk reduction is supported by certain
studies (14,19–23),
whereas earlier analyses questioned the benefit once intestinal
metaplasia or dysplasia was established (13,24).
Paired or longitudinal immune and molecular trajectories are
represented by certain studies (53,54,76),
as well as structural trajectories (15,16),
microbial trajectories (35,36)
and direct post-eradication stromal/immune-associated remodeling in
chronic atrophic gastritis (55).
H. pylori, Helicobacter pylori; OLGIM, Operative Link on
Gastric Intestinal Metaplasia Assessment; Me, methyl group.

Figure 1.

Competing trajectories of gastric tissue recovery and residual risk after eradication. The dominant pathway emphasizes established eradication-associated risk reduction followed by heterogeneous tissue recovery. Solid arrows denote directly observed post-eradication changes or established structural associations; dashed arrows denote candidate or unresolved relationships that require longitudinal validation. Dotted connectors indicate baseline pathological modifiers. Studies (13,14,19–24) address eradication-associated risk reduction and residual risk. Overall and metachronous risk reduction is supported by certain studies (14,19–23), whereas earlier analyses questioned the benefit once intestinal metaplasia or dysplasia was established (13,24). Paired or longitudinal immune and molecular trajectories are represented by certain studies (53,54,76), as well as structural trajectories (15,16), microbial trajectories (35,36) and direct post-eradication stromal/immune-associated remodeling in chronic atrophic gastritis (55). H. pylori, Helicobacter pylori; OLGIM, Operative Link on Gastric Intestinal Metaplasia Assessment; Me, methyl group.

Immune remodeling during chronic H. pylori infection

Myeloid and antigen-presentation programs

Monocytes, macrophages, dendritic cells and neutrophils participate early in the gastric response to H. pylori (50). Single-cell data from infected human tissue show altered monocyte-to-macrophage differentiation and reduced phagocytic or antigen-presentation programs, while atlases of precursor lesions and established cancer reveal myeloid states that extend beyond conventional binary M1/M2 labels (61,72,77–79). These observations establish heterogeneity during infection or in tumors, not persistence after eradication.

Studies of established gastric cancer have described secreted phosphoprotein 1 (SPP1)-positive macrophage-stromal interactions associated with matrix remodeling and immune suppression (80–82). Within the present framework, these findings identify spatial relationships for testing in paired precursor tissue and do not define a precursor phenotype.

Therefore, post-eradication studies should prioritize anatomically matched measures of antigen-presentation capacity, phagocytic function and myeloid-T-cell or myeloid-stromal interactions rather than macrophage abundance or binary polarization labels. A credible precursor-lesion signal requires concordant functional evidence, or a proxy that has been validated against such evidence. Within the tissue-based framework, a post-eradication myeloid signal would be informative only if it persists in anatomically matched mucosa, retains functional abnormality and contributes information beyond structural and infectious explanations.

T-cell regulation and immune surveillance

Effective immune surveillance depends on a sequence of antigen capture, presentation, T-cell priming, clonal expansion and effector activity. Infection-stage data indicate that impaired antigen-presentation programs can coexist with altered T-cell states (61), but no study of precursor tissue has followed this coupled disturbance longitudinally after eradication.

H. pylori-specific immunity includes protective, tolerogenic and tissue-damaging components. Human studies have identified H. pylori-specific regulatory T-cell and T helper 1 responses (83,84). Experimental models suggest that regulatory T cells, dendritic-cell-mediated regulatory T-cell skewing, γ-glutamyl transpeptidase/VacA-dependent tolerance and inflammasome-related signaling influence microbial persistence and tissue injury (85–88), while the interleukin (IL)-23/IL-17 axis provides an additional inflammatory pathway (89). The relevant question is not whether these programs operate during infection, but whether their balance is restored once the organism has been cleared.

TRMs provide a more specific candidate cellular substrate for localized immune persistence. Gastric H. pylori-specific CD8+ TRM populations have been characterized in humans and experimental models, including CagA-specific cells with antigen-specific effector activity (63). A 2025 human study further reported increased gastric mucosal CD8+ TRMs in H. pylori-infected subjects, recruitment through the C-X-C motif chemokine receptor 5/C-X-C motif chemokine ligand 13 axis and enhanced interferon-γ (IFN-γ) and tumor necrosis factor-α production (90). Experimental studies have demonstrated that CagA-specific gastric CD8+ TRMs contribute to controlling H. pylori during early infection (63), while a subsequent eradication and reinfection study showed that CagA-dependent Hobit+ gastric TRMs can persist long term and confer protection against reinfection (91). These findings establish biological plausibility for a durable resident T-cell compartment, but they do not demonstrate that functionally abnormal TRM populations persist after eradication in high-risk human precursor lesions or independently contribute to subsequent neoplasia.

Notably, an ex vivo single-cell analysis of a gastric intestinal metaplasia biopsy from one patient identified a resident-memory CD8+ T-cell cluster, providing direct precursor-stage evidence for the presence of a TRM compartment (64). However, this single-biopsy tissue-engineering study was designed to evaluate ex vivo cellular responses rather than longitudinal persistence after H. pylori eradication.

Therefore, within the present framework, TRM should be treated as a candidate substrate for persistence rather than evidence that persistence has occurred. Their relevance would require longitudinally matched assessment of residency-associated phenotype, antigen specificity or function after confirmed eradication, together with concurrent measurement of structural and epithelial-field burden. More broadly, T-cell phenotype or abundance becomes clinically informative only when persistent residency-associated or functional abnormalities are demonstrated after eradication and remain distinct from competing tissue-field explanations.

Exposure history and the gastric microbiome

Clinical records commonly reduce H. pylori status to positive, negative or eradicated. This simplification obscures distinctions among active infection, remote infection, time since eradication and reinfection, while antibiotic exposure, acid suppression and the diagnostic method can influence infection ascertainment or microbial measurements (11,17,29,35,36). Longitudinal human studies also suggest that microbial recovery is not uniform. In a randomized paired-biopsy study, eradication increased microbial diversity, but specific microbial patterns were associated with persistent inflammation, atrophy or intestinal metaplasia at one year (35). A 2026 longitudinal study of patients treated endoscopically for gastric cancer likewise identified substantial shifts in community structure after eradication (36). These findings position the microbiome as a contextual modifier and a competing explanation; neither demonstrates a persistent immune mechanism in precursor tissue from individuals without previous gastric neoplasia.

Therefore, exposure history should be reconstructed explicitly rather than represented by a binary category. Microbiome data should remain candidate modifiers until they show reproducible value independent of medication, diet, geography, infection status and morphologic disease (8,34–39). Therefore, within the tissue-based framework, infection history and microbiome composition should be treated as mandatory competing variables and contextual modifiers rather than as evidence of persistent immune dysfunction themselves.

Metaplastic and stromal substrates of persistence

Gastric intestinal metaplasia and persistent tissue state

Gastric intestinal metaplasia is a plausible substrate for persistent tissue change as regenerative reprogramming, gland reconstruction, immune infiltration, stromal alteration and spatial heterogeneity coexist within the lesion (56,57,62,70–75). Spasmolytic polypeptide-expressing metaplasia models support continuity between injury and altered tissue architecture, but do not demonstrate immune persistence after eradication (92–96).

Genomic, single-cell and methylation studies show that intestinal metaplasia contains distinct epithelial trajectories, clonal structures and subtype-specific methylation programs (56,57,74,75). Therefore, any immune association must be evaluated after adjustment for the extent and subtype of metaplasia, dysplasia, OLGIM stage and epithelial-field burden.

The practical question is whether immune or stromal measurements retain risk information after these established structural variables have been considered. Until this has been demonstrated, a high-risk immune label would be premature.

Stromal-gland interactions and spatial organization

Across cancer biology, inflammation can remodel tissue through cytokine signaling, extracellular-matrix turnover, angiogenesis and regenerative programs (97,98). However, in gastric precursor mucosa, a putatively persistent immune mechanism must be demonstrated within the tissue architecture rather than inferred from transient inflammatory-cell counts.

Fibroblasts may link altered glands to immune-cell behavior. Direct post-eradication human evidence is available from a 2026 single-cell study of 22 human gastric antral mucosal samples spanning different stages of H. pylori infection and post-eradication chronic atrophic gastritis (55). The study identified two subpopulations of immunomodulatory cancer-associated fibroblasts (iCAFs): Cellular communication network factor 2-expressing iCAF1 and Complement component 3-expressing iCAF3. These labels represent transcriptomically defined fibroblast subpopulations characterized by their respective marker-expression profiles. Both subpopulations remained detectable after eradication, particularly in patients without pathological improvement, and were associated with an immunosuppressive stromal-epithelial niche (55). This study strengthens the case for stromal persistence in precursor mucosa, but its stage-stratified design lacked anatomically matched paired sampling and prospective neoplastic outcomes. Tumor-stage SPP1-positive macrophage-fibroblast networks remain mechanistic analogies rather than precursor-stage proof (80–82).

Taken together, direct post-eradication human observations and tumor-stage studies identify plausible stromal-immune relationships, but only the former sample precursor mucosa after eradication. Establishing a persistent immune mechanism still requires anatomically standardized paired human tissue with functional validation. Therefore, Fig. 2 distinguishes observed post-eradication stromal remodeling from candidate immune-persistence relationships that still require longitudinal validation.

Tissue context of
infection-associated remodeling and candidate persistence after
eradication. The visually dominant left-to-right pathway separates
evidence-supported observations from relationships that still
require longitudinal validation. (A) The infection/precursor-stage
layer summarizes epithelial metaplasia, myeloid and
antigen-presentation programs, altered T-cell states and gastric
tissue-resident memory T-cell biology (56,57,61–64,69–75,90,91).
Reference 64 demonstrates a resident-memory CD8+ T-cell cluster in
a single ex vivo human gastric intestinal metaplasia biopsy
and should not be interpreted as evidence of post-eradication
persistence. (B) The candidate layer addresses whether such tissue
states persist within the same individuals, remain functionally
abnormal and predict outcomes independently of structural and
epithelial-field burden. The localized immune-stromal interactions
depicted in panel B represent tumor-stage mechanistic analogies
rather than direct evidence of post-eradication stromal remodeling
in gastric precursor mucosa (80–82).
Solid connectors denote evidence-supported associations; dashed
connectors denote indirect, candidate or hypothesis-level links.
APC, antigen-presenting cell; H. pylori, Helicobacter
pylori; ECM, extracellular matrix.

Figure 2.

Tissue context of infection-associated remodeling and candidate persistence after eradication. The visually dominant left-to-right pathway separates evidence-supported observations from relationships that still require longitudinal validation. (A) The infection/precursor-stage layer summarizes epithelial metaplasia, myeloid and antigen-presentation programs, altered T-cell states and gastric tissue-resident memory T-cell biology (56,57,61–64,69–75,90,91). Reference 64 demonstrates a resident-memory CD8+ T-cell cluster in a single ex vivo human gastric intestinal metaplasia biopsy and should not be interpreted as evidence of post-eradication persistence. (B) The candidate layer addresses whether such tissue states persist within the same individuals, remain functionally abnormal and predict outcomes independently of structural and epithelial-field burden. The localized immune-stromal interactions depicted in panel B represent tumor-stage mechanistic analogies rather than direct evidence of post-eradication stromal remodeling in gastric precursor mucosa (80–82). Solid connectors denote evidence-supported associations; dashed connectors denote indirect, candidate or hypothesis-level links. APC, antigen-presenting cell; H. pylori, Helicobacter pylori; ECM, extracellular matrix.

Human evidence after eradication

Directness, recovery heterogeneity and evidence ceiling
Direct evidence of immune reversibility

The most direct longitudinal evidence of immune-function change after eradication comes from Ihan et al (53). In 24 patients with duodenal ulcer, gastric mucosal T-cell CD25 expression and IFN-γ production declined at 3 and 12 months after H. pylori eradication (53). These findings demonstrate reversibility of selected infection-dependent T-cell responses. However, the study population did not have gastric precursor disease, and the immune environment of duodenal ulcers may differ substantially from that of extensive atrophy or intestinal metaplasia. Therefore, the observed reversibility cannot be assumed to generalize to high-risk precursor mucosa. The decline in CD25 expression and IFN-γ production could theoretically reflect contraction or phenotypic remodeling of a tissue-resident T-cell compartment after removal of bacterial antigen, but the study did not phenotype residency-associated markers or distinguish resident from recirculating T cells. Therefore, TRM clearance cannot be inferred from these data. Only a restricted set of T-cell functions was examined, and neither epithelial-field burden nor subsequent neoplastic outcomes were assessed.

Molecular and structural recovery

Paired molecular and structural studies show discordant tissue recovery, but do not directly establish persistent immune function. A randomized, placebo-controlled study examined 54 gastric biopsies from 27 participants and identified changes in gene expression one year after eradication, demonstrating molecular responsiveness in gastric precursor disease (76). Among 65 patients with intestinal metaplasia, 44 (67.7%) retained metaplasia after a mean follow-up of 33.9 months, and persistence was associated with greater baseline nuclear β-catenin expression (15). In a prospective cohort of 172 patients followed histologically for up to 17 years, atrophy improved after eradication, whereas intestinal metaplasia did not change significantly at either biopsy site (16). Therefore, molecular or inflammatory improvement may coexist with structural persistence, a pattern that primarily supports epithelial and tissue-field explanations.

Outcome-linked and contextual evidence

Among the available studies, Kim et al (54) provide the closest currently available human evidence linking post-eradication immune remodeling to a clinical neoplastic outcome. In 36 patients who developed metachronous gastric neoplasia after eradication and 36 matched controls, post-eradication histologic and CD8-associated trajectories differed between outcome groups (54). This head-to-head comparison gives the study greater evidentiary weight than a purely cross-sectional immune association. Nevertheless, the measurements were immunohistochemical proxies rather than direct functional assays, and all participants had previously undergone endoscopic resection for gastric neoplasia, implying a pre-existing neoplastic epithelial and stromal field. Therefore, the study supports an outcome-associated immune trajectory but does not establish persistent immune dysfunction as an independent risk mechanism in a primary-prevention population. Separately, a 2026 single-cell study of 22 human antral mucosal samples spanning infected and post-eradication chronic atrophic gastritis identified persistent immunomodulatory fibroblast states and an immunosuppressive stromal-epithelial niche after eradication (55). This provides direct post-eradication human tissue evidence of microenvironmental persistence, but not paired longitudinal immune-function evidence or prospective neoplastic outcome association. Microbial studies provide additional context, including a randomized cohort showing marked microbial remodeling at one year after eradication, with specific taxa associated with persistent inflammation, atrophy or intestinal metaplasia (35), and a 2026 post-resection cohort which showed non-uniform microbiome changes after eradication (36). These observations are contextual rather than functional immune evidence.

Overall interpretation of the human evidence

The evidence hierarchy is complementary rather than uniform. Ihan et al (53) provide the most direct longitudinal evidence of selected immune-function reversibility, whereas Kim et al (54) provide the strongest currently available outcome-linked immune evidence. Neither study establishes a persistent, functionally defined immune state that independently predicts incident neoplasia in an eradicated primary-prevention population. Molecular, structural, microbial and stromal single-cell observations support heterogeneous recovery but arise from non-equivalent populations and biological domains. The 2026 post-eradication single-cell study increases the directness of tissue-persistence evidence, as it samples chronic atrophic gastritis after eradication, but does not complete the within-person functional-outcome chain (55). Among eligible studies identified through the present search, none assessed immune persistence and function, epithelial-field burden and prospective incident outcomes in the same eradicated individuals without previous gastric neoplasia. Therefore, current human evidence supports heterogeneous recovery, but not an independent persistent immune state.

Post-eradication trajectories

A total of four longitudinal patterns are analytically useful. A normalizing trajectory denotes resolution of active inflammation and infection-dependent immune activation (53,76). Structural persistence refers to retained atrophy or intestinal metaplasia (15,16); epithelial clonal and methylation fields should be treated as competing tissue-field explanations rather than assumed post-eradication trajectories (56,57). A persistently altered trajectory requires reproducible functional abnormalities, pathway-level changes or biologically validated spatial features after morphology and inflammation have been considered (53–55,61,62). Reinfection, inconsistent biopsy location, medication exposure, inadequate tissue or assay instability define an indeterminate trajectory (11,17,27,35,59,60,65). These are research constructs, not clinical labels.

The most informative confirmation cohort would include individuals with verified eradication, no previous gastric neoplasia and a guideline-defined high-risk precursor phenotype, such as OLGIM III–IV or extensive endoscopic intestinal metaplasia (12,17,28,30,31). The key comparison is not simply between infected and eradicated tissue, but between eradicated patients with and without reproducible immune abnormalities after concurrent assessment of morphology, epithelial-field burden, reinfection, medication exposure and sampling location. Post-resection cohorts remain valuable for secondary validation, but cannot replace primary-prevention evidence, as previous neoplasia implies a different epithelial and stromal field.

Falsification criteria

The hypothesis should be tested against explicit failure criteria. A candidate feature must recur in standardized paired biopsies after active inflammation, reinfection, medication effects and sampling variation have been addressed (11,17,27,35), and it must not simply track OLGIM stage, metaplasia extent, epithelial clone burden, biopsy site or baseline inflammation (12,26,27,56,57). A pathway-level or spatial proxy requires validation against functional immune activity and stage-appropriate outcomes (53–55,59,60,62,65). Resolution after eradication (53,76), inconsistent replication or absence of information beyond morphologic and epithelial-field measures (12,56,57,59,65) would favor the more limited interpretation of infection-associated remodeling.

Discussion

Taken together, the evidence supports a staged rather than a unitary interpretation. Eradication reduces primary and metachronous gastric neoplasia (19–23) and reverses selected infection-dependent T-cell responses (53), whereas structural and microbial abnormalities may persist (15,16,35,36). Clonal and epigenetic studies reveal additional heterogeneity within the epithelial field, but its trajectory after eradication remains unresolved (56,57). Among the studies identified through the present search, none provided longitudinal primary-prevention evidence that a persistent immune feature predicted incident neoplasia independently of structural and epithelial-field burden. Therefore, the remaining issues are the adequacy of competing explanations, the evidence needed for confirmation and the limits of clinical translation.

The present review organized the available evidence according to disease stage, directness and competing explanations rather than proposing a new disease label. Distinguishing remodeling during infection from persistence after eradication, and biological function from clinical utility, clarifies what is required before an immune-associated signal can be interpreted independently of structural disease, epithelial-field alterations or exposure misclassification.

Competing explanations and comparative models

Residual risk may arise through several non-exclusive mechanisms. Metaplastic architecture may remain abnormal as gland identity and tissue organization reverse slowly, if at all. Clonal and methylation fields within intestinal metaplasia may account for outcome variation independently of immune measurements, although their persistence after eradication has not been established (56,57). Host susceptibility and dietary exposure may modify baseline risk (32–34), while infection status and gastric microbial ecology may vary with eradication and geography (8,29,35–39). Therefore, medication exposure, biopsy location and sampling quality should be recorded as design variables. A persistent immune signal may be biologically genuine yet remain secondary to a more influential structural or epithelial process.

The critical analytical test is whether mucosal immune measurements explain outcome variation after structural, epithelial, infectious and exposure-related alternatives have been incorporated adequately. Adding an immune panel to an incomplete baseline model would exaggerate its contribution. Therefore, Table III treats competing explanations as obligatory comparators rather than peripheral caveats.

Table III.

Alternative explanations and discriminating tests.

Table III.

Alternative explanations and discriminating tests.

ModelProposed mechanismExpected observationDiscriminating test(Refs.)
Persistent metaplastic burdenIrreversible or slowly reversible glandular architecture carries residual risk.Risk follows the extent, subtype and distribution of atrophy or metaplasia.Adjust for OLGIM/EGGIM, metaplasia extent and subtype, and repeated histology.(15,16,25,26,30,31)
Epithelial clonal/epigenetic fieldClonal and methylation fields within intestinal metaplasia provide a competing epithelial explanation; their persistence specifically after eradication remains unproven.Epithelial-field measures attenuate or outweigh the outcome association attributed to immune features.Quantify a minimum structural field comprising OLGIM stage, metaplasia extent/distribution and subtype; incorporate EGGIM where available; and, in molecularly profiled cohorts, prespecify a quantitative methylation or clonal/mutational-burden measure. Test whether candidate immune features retain independent and incremental outcome information beyond these variables.(56,57)
Occult infection or reinfectionContinued microbial stimulation sustains inflammation.Persistent features disappear when infection is excluded rigorously.Use multiple tests of eradication, longitudinal microbiology and sensitivity analyses.(11,17,29)
Microbiome or exposure modifierNon-H. pylori microbiota, diet and medication-related effects on infection ascertainment or microbial measurement alter the observed tissue state.Associations vary with geography, eradication status, medication exposure or diet.Standardize exposure measurement, document antibiotic use and acid suppression, and test replication across geographic settings (8,11,17,34–39)(8,11,17,34–39)
Candidate immune-associated persistenceA localized functional state, or a functionally validated proxy, remains after eradication and contributes to risk.Immune features persist after eradication and add outcome information beyond competing models.Use paired functional, pathway-level or validated spatial assessment; compare competing models; validate externally; and demonstrate clinically meaningful incremental value.(53–55,59,60,65,66)

[i] EGGIM, Endoscopic Grading of Gastric Intestinal Metaplasia; H. pylori, Helicobacter pylori; OLGIM, Operative Link on Gastric Intestinal Metaplasia Assessment.

A clinically credible baseline model should cover four domains. Exposure assessment should reconstruct current or previous H. pylori infection, timing of eradication, reinfection, antibiotic use, acid suppression, diet and relevant host susceptibility (11,17,29,32–36). Morphologic assessment should include high-quality endoscopy, Sydney-system pathology, OLGA/OLGIM stage, EGGIM where high-quality endoscopic mapping is available, the extent and anatomical distribution of metaplasia, metaplasia subtype and dysplasia (12,25–31). Therefore, a minimum structural epithelial-field core should include OLGIM stage, metaplasia extent/distribution and subtype. In molecularly profiled cohorts, at least one prespecified quantitative epithelial-field measure, such as methylation burden or clonal/mutational burden, should additionally be evaluated where tissue availability permits (56,57). Only then should a small prespecified set of immune-function measurements or functionally validated proxies be tested for added value.

Analysis should begin with the clinical, morphologic, exposure and epithelial-field model. Candidate immune markers can then be added to assess independent and incremental risk information. Prespecification, transparent reporting, calibration, external validation, risk-of-bias assessment and clinical utility should follow established principles for biomarkers and prediction models (59,60,65,66). Molecular subtypes defined in established gastric cancer (99,100) may suggest biological continuity but cannot substitute for measurements in precursor-lesion mucosa. Likewise, digital pathology is a measurement platform, not evidence that the proposed biological state exists.

Evidence required for confirmation and translation

Confirmation requires a longitudinal cohort of individuals without previous gastric neoplasia. Each participant should undergo verified assessment of eradication or reinfection, anatomically standardized paired sampling, and direct measurement of immune function or a functionally validated proxy. Morphology, epithelial-field burden and prospective dysplasia or gastric cancer outcomes should be assessed concurrently. Cross-study triangulation can justify further investigation but cannot replace this within-cohort chain. Sampling intervals, assays, candidate measurements and analytical plans should be prespecified and reported transparently (59,60,65). The corresponding measurement domains, limitations of the available direct evidence and key longitudinal tests are summarized in Table SIII. High-dimensional atlases and post-resection associations can identify candidate signals but cannot establish persistence or clinical relevance on their own.

Incident dysplasia or gastric cancer in individuals without previous gastric neoplasia should serve as the primary clinical endpoints, with metachronous neoplasia after endoscopic resection used for secondary validation. Biological persistence requires exposure linkage, localization and demonstrable function. Clinical utility additionally requires technical stability, external validation, calibration, incremental value and a measurable improvement in surveillance decisions (59,60,65,66). The longitudinal validation sequence integrating these requirements is summarized in Fig. 3.

Longitudinal study pathway for
evaluating post-eradication mucosal immune trajectories. The main
pathway visually prioritizes baseline assessment, confirmation of
eradication, anatomically standardized paired tissue, follow-up and
clinical outcomes. Solid connectors denote required measurements or
evidence-supported analytical steps; dashed connectors denote
hypothesized biological links that remain to be validated.
Biological support requires exposure linkage, localization,
persistence and functional evidence, or a proxy validated against
immune function. Clinical translation additionally requires
independent outcome association, external validation, calibration,
incremental value and a meaningful effect on surveillance decisions
(59,60,65,66). A
signal that fails at either stage should remain a research
observation rather than a clinical risk marker. H. pylori,
Helicobacter pylori.

Figure 3.

Longitudinal study pathway for evaluating post-eradication mucosal immune trajectories. The main pathway visually prioritizes baseline assessment, confirmation of eradication, anatomically standardized paired tissue, follow-up and clinical outcomes. Solid connectors denote required measurements or evidence-supported analytical steps; dashed connectors denote hypothesized biological links that remain to be validated. Biological support requires exposure linkage, localization, persistence and functional evidence, or a proxy validated against immune function. Clinical translation additionally requires independent outcome association, external validation, calibration, incremental value and a meaningful effect on surveillance decisions (59,60,65,66). A signal that fails at either stage should remain a research observation rather than a clinical risk marker. H. pylori, Helicobacter pylori.

Clinical implications and application limits

At present, no tissue-based test derived from this framework is ready for routine use. Surveillance should continue to follow established recommendations and high-quality endoscopic and histologic assessment, and gastric dysplasia should be managed according to existing standards (12,17,28,101,102). The immediate translational value lies in defining research-eligible populations rather than changing care. Patients with confirmed eradication and OLGIM III–IV or extensive intestinal metaplasia should continue to be managed under current guidance, while candidate immune or spatial assays should be confined to prospective studies of individuals without previous gastric neoplasia and evaluated against incident dysplasia or cancer (12,17,28,30,31).

Any viable assay must be parsimonious, reproducible across biopsy sites and compatible with routine pathology. Adoption would require sufficient clinical benefit to offset additional biopsies, cost, false reassurance and unnecessary endoscopy. Digital pathology may facilitate measurement, but its availability does not establish the existence of the proposed state or the clinical validity of a risk classifier.

Positioning relative to recent reviews

Recent reviews and perspectives have primarily addressed residual-risk management after eradication, infection-phase oncogenic signaling or immune tolerance in established gastric cancer (103–105). The present review instead focuses on precursor-lesion mucosa after eradication in individuals without previous gastric neoplasia and asks whether paired immune measurements add information beyond structural and epithelial-field burden. This emphasis shifts the discussion from pathway cataloguing to directness of evidence, competing explanations, falsifiability and clinical increment.

Limitations and research priorities

The present review had several limitations. First, the integrated human evidence chain remains incomplete. Among eligible studies identified through the present search, none measured confirmed exposure, paired immune persistence and function, epithelial-field burden, incident cancer outcomes and incremental clinical value within the same prevention cohort. Available studies triangulate across non-equivalent populations and biological domains, and only selected T-cell measurements assess immune function directly. The incorporated TRM studies establish infection-stage biology, experimental durability or precursor-stage presence, but do not provide longitudinal evidence of abnormal TRM persistence after eradication in high-risk human precursor cohorts (63,64,90,91). The 2026 post-eradication single-cell study strengthens direct evidence of persistent stromal/immune-associated remodeling, but its stage-stratified design does not establish within-person persistence or clinical outcome independence (55). Second, the concept-driven narrative design, restriction to English-language reports and reliance on published studies may introduce selection, availability and interpretive bias. Third, several proposed myeloid-stromal and spatial mechanisms still derive from established gastric cancer, animal models, organoids or other tumor types and cannot be assumed to operate in precursor mucosa after eradication (47,48,77,80–82,92–96,106).

The strongest outcome-linked immune observations were obtained in patients with previous gastric neoplasia (54), limiting generalizability to primary-prevention populations. Previous neoplasia also implies a different epithelial and stromal field, making these cohorts unsuitable as the sole basis for a marker intended for primary prevention. Even a reproducible mucosal immune state may prove clinically unusable because of sampling variation, platform dependence, cost, overfitting or a lack of incremental value.

The highest-priority next step is multicenter validation using paired biopsies from individuals without previous gastric neoplasia (12,17,53–55). Repeated assessment of eradication status and immune function should be interpreted alongside morphology, epithelial clonal or methylation burden and prospective outcomes in the same participants (11,12,53,55–57). The decisive question is whether a parsimonious immune assay improves risk stratification or surveillance decisions beyond a complete clinical, morphologic, exposure and epithelial-field baseline (12,17,59,60,65,66).

Conclusions

H. pylori eradication reduces gastric cancer risk but does not restore all high-risk gastric mucosa to a uniform biological state. Current human evidence supports heterogeneous post-eradication recovery, but does not yet establish a persistent, functionally defined immune state that predicts incident neoplasia independently of structural and epithelial-field burden. Therefore, the principal contribution of the present review is a falsifiable framework that separates immune persistence from residual inflammation, tissue-field damage and clinical utility. The immediate research priority is a prospective paired-biopsy cohort in individuals without previous gastric neoplasia that integrates verified eradication, immune function, epithelial-field measurements and incident outcomes. Until such evidence is available, candidate immune markers should remain investigational, and surveillance should continue to follow established endoscopic and histologic criteria.

Supplementary Material

Supporting Data

Acknowledgements

Not applicable.

Funding

This review was supported by the Yunnan Provincial Department of Science and Technology Kunming Medical University Special Projects (grant no. 202401AY070001-197).

Availability of data and materials

Not applicable.

Authors' contributions

JC and BT contributed to study conception, literature review, manuscript drafting and table organization. LZ and JC supervised the study design, revised key academic content and approved the final manuscript. All authors contributed to writing and revising the manuscript. All authors read and approved the final version of the manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Glossary

Abbreviations

Abbreviations:

EGGIM

Endoscopic Grading of Gastric Intestinal Metaplasia

OLGA

Operative Link on Gastritis Assessment

OLGIM

Operative Link on Gastric Intestinal Metaplasia Assessment

TRM

tissue-resident memory T cell

References

1 

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI

2 

Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020. View Article : Google Scholar : PubMed/NCBI

3 

de Martel C, Georges D, Bray F, Ferlay J and Clifford GM: Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health. 8:e180–e190. 2020. View Article : Google Scholar : PubMed/NCBI

4 

Plummer M, Franceschi S, Vignat J, Forman D and de Martel C: Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 136:487–490. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Wroblewski LE, Peek RM Jr and Wilson KT: Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clin Microbiol Rev. 23:713–739. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Amieva M and Peek RM Jr: Pathobiology of Helicobacter pylori-induced gastric cancer. Gastroenterology. 150:64–78. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Polk DB and Peek RM Jr: Helicobacter pylori: Gastric cancer and beyond. Nat Rev Cancer. 10:403–414. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Wizenty J and Sigal M: Helicobacter pylori, microbiota and gastric cancer-principles of microorganism-driven carcinogenesis. Nat Rev Gastroenterol Hepatol. 22:296–313. 2025. View Article : Google Scholar : PubMed/NCBI

9 

Correa P: Human gastric carcinogenesis: A multistep and multifactorial process-first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 52:6735–6740. 1992.PubMed/NCBI

10 

Liabeuf D, Oshima M, Stange DE and Sigal M: Stem cells, Helicobacter pylori, and mutational landscape: Utility of preclinical models to understand carcinogenesis and to direct management of gastric cancer. Gastroenterology. 162:1067–1087. 2022. View Article : Google Scholar : PubMed/NCBI

11 

Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, et al: Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut. 71:1724–1762. 2022. View Article : Google Scholar : PubMed/NCBI

12 

Dinis-Ribeiro M, Libânio D, Uchima H, Spaander MCW, Bornschein J, Matysiak-Budnik T, Tziatzios G, Santos-Antunes J, Areia M, Chapelle N, et al: Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European society of gastrointestinal endoscopy (ESGE), European Helicobacter and microbiota study group (EHMSG) and European society of pathology (ESP) guideline update 2025. Endoscopy. 57:504–554. 2025. View Article : Google Scholar : PubMed/NCBI

13 

Chen HN, Wang Z, Li X and Zhou ZG: Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: Evidence from a meta-analysis. Gastric Cancer. 19:166–175. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Fu Q, Yu H, Liu M, Chen L, Chen W, Wang Z and Li W: Effect of Helicobacter pylori eradication on gastric cancer risk in patients with intestinal metaplasia or dysplasia: A meta-analysis of randomized controlled trials. Front Microbiol. 16:15305492025. View Article : Google Scholar : PubMed/NCBI

15 

Hung KH, Wu JJ, Yang HB, Su LJ and Sheu BS: Host Wnt/beta-catenin pathway triggered by Helicobacter pylori correlates with regression of gastric intestinal metaplasia after H. pylori eradication. J Med Microbiol. 58:567–576. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Kodama M, Okimoto T, Mizukami K, Hirashita Y, Wada Y, Fukuda M, Matsunari O, Okamoto K, Ogawa R, Fukuda K, et al: Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study. J Gastroenterol Hepatol. 36:2210–2216. 2021. View Article : Google Scholar : PubMed/NCBI

17 

Shah SC, Wang AY, Wallace MB and Hwang JH: AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: Expert review. Gastroenterology. 168:405–416.e1. 2025. View Article : Google Scholar : PubMed/NCBI

18 

Park JY: Population-based Helicobacter pylori screen-and-treat strategies for gastric cancer prevention: Guidance on implementation. IARC Working Group Reports Lyon (FR): International Agency for Research on Cancer; 2025

19 

Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS and Graham DY: Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology. 150:1113–1124.e5. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Ford AC, Yuan Y, Park JY, Forman D and Moayyedi P: Eradication therapy to prevent gastric cancer in Helicobacterpylori-positive individuals: Systematic review and meta-analysis of randomized controlled trials and observational studies. Gastroenterology. 169:261–276. 2025. View Article : Google Scholar : PubMed/NCBI

21 

Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B and Nam BH: Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 378:1085–1095. 2018. View Article : Google Scholar : PubMed/NCBI

22 

Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B and Joo J: Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 382:427–436. 2020. View Article : Google Scholar : PubMed/NCBI

23 

Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S and Asaka M; Japan Gast Study Group, : Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet. 372:392–397. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Rokkas T, Rokka A and Portincasa P: A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 30:414–423. 2017.PubMed/NCBI

25 

Rugge M, Genta RM, Fassan M, Valentini E, Coati I, Guzzinati S, Savarino E, Zorzi M, Farinati F and Malfertheiner P: OLGA gastritis staging for the prediction of gastric cancer risk: A long-term follow-up study of 7436 patients. Am J Gastroenterol. 113:1621–1628. 2018. View Article : Google Scholar : PubMed/NCBI

26 

Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NCT and Kuipers EJ: The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 71:1150–1158. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Dixon MF, Genta RM, Yardley JH and Correa P: Classification and grading of gastritis: The updated sydney system. International workshop on the histopathology of gastritis, houston 1994. Am J Surg Pathol. 20:1161–1181. 1996. View Article : Google Scholar : PubMed/NCBI

28 

Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, Garrido M, Kikuste I, Megraud F, Matysiak-Budnik T, et al: Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European society of gastrointestinal endoscopy (ESGE), European Helicobacter and microbiota study group (EHMSG), European society of pathology (ESP), and sociedade portuguesa de endoscopia digestiva (SPED) guideline update 2019. Endoscopy. 51:365–388. 2019.PubMed/NCBI

29 

Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, et al: Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 64:1353–1367. 2015. View Article : Google Scholar : PubMed/NCBI

30 

den Hollander WJ, Holster IL, den Hoed CM, Capelle LG, Tang TJ, Anten MP, Prytz-Berset I, Witteman EM, ter Borg F, Hartog G, et al: Surveillance of premalignant gastric lesions: A multicentre prospective cohort study from low incidence regions. Gut. 68:585–593. 2019. View Article : Google Scholar : PubMed/NCBI

31 

Marcos P, Brito-Gonçalves G, Libânio D, Pita I, Castro R, Sá I, Dinis-Ribeiro M and Pimentel-Nunes P: Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: Can we replace histology assessment also in the west? Gut. 69:1762–1768. 2020. View Article : Google Scholar : PubMed/NCBI

32 

El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 404:398–402. 2000. View Article : Google Scholar : PubMed/NCBI

33 

González CA, Sala N and Capellá G: Genetic susceptibility and gastric cancer risk. Int J Cancer. 100:249–260. 2002. View Article : Google Scholar : PubMed/NCBI

34 

Tsugane S and Sasazuki S: Diet and the risk of gastric cancer: Review of epidemiological evidence. Gastric Cancer. 10:75–83. 2007. View Article : Google Scholar : PubMed/NCBI

35 

Sung JJY, Coker OO, Chu E, Szeto CH, Luk STY, Lau HCH and Yu J: Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut. 69:1572–1580. 2020. View Article : Google Scholar : PubMed/NCBI

36 

Song CH, Choi Y, Kim N, Ha S, Park JH, Lee HK, Shin CM and Ahn S: Longitudinal remodeling of gastric microbiota following Helicobacter pylori eradication reveals an eradication-associated microbial signature in gastric cancer. Front Cell Infect Microbiol. 16:18484372026. View Article : Google Scholar : PubMed/NCBI

37 

Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC and Figueiredo C: Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 67:226–236. 2018. View Article : Google Scholar : PubMed/NCBI

38 

Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WKK, Wong SH, Chen Z, Sung JJY and Yu J: Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 67:1024–1032. 2018. View Article : Google Scholar : PubMed/NCBI

39 

Gantuya B, El-Serag HB, Matsumoto T, Ajami NJ, Oyuntsetseg K, Azzaya D, Uchida T and Yamaoka Y: Gastric microbiota in Helicobacter pylori-negative and -positive gastritis among high incidence of gastric cancer area. Cancers (Basel). 11:5042019. View Article : Google Scholar : PubMed/NCBI

40 

Salama NR, Hartung ML and Müller A: Life in the human stomach: Persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 11:385–399. 2013. View Article : Google Scholar : PubMed/NCBI

41 

Backert S, Tegtmeyer N and Fischer W: Composition, structure and function of the Helicobacter pylori cag pathogenicity island encoded type IV secretion system. Future Microbiol. 10:955–965. 2015. View Article : Google Scholar : PubMed/NCBI

42 

Hatakeyama M: Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 4:688–694. 2004. View Article : Google Scholar : PubMed/NCBI

43 

Cover TL and Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology. 136:1863–1873. 2009. View Article : Google Scholar : PubMed/NCBI

44 

Boquet P and Ricci V: Intoxication strategy of Helicobacter pylori VacA toxin. Trends Microbiol. 20:165–174. 2012. View Article : Google Scholar : PubMed/NCBI

45 

Fischer W: Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus. FEBS J. 278:1203–1212. 2011. View Article : Google Scholar : PubMed/NCBI

46 

Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM Jr, Azuma T and Hatakeyama TM: Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 26:4617–4626. 2007. View Article : Google Scholar : PubMed/NCBI

47 

Bessède E, Dubus P, Mégraud F and Varon C: Helicobacter pylori infection and stem cells at the origin of gastric cancer. Oncogene. 34:2547–2555. 2015. View Article : Google Scholar : PubMed/NCBI

48 

Hayakawa Y, Fox JG and Wang TC: The origins of gastric cancer from gastric stem cells: Lessons from mouse models. Cell Mol Gastroenterol Hepatol. 3:331–338. 2017. View Article : Google Scholar : PubMed/NCBI

49 

Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR and Wang TC: Gastric cancer originating from bone marrow-derived cells. Science. 306:1568–1571. 2004. View Article : Google Scholar : PubMed/NCBI

50 

Kusters JG, van Vliet AHM and Kuipers EJ: Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 19:449–490. 2006. View Article : Google Scholar : PubMed/NCBI

51 

Peek RM Jr and Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2:28–37. 2002. View Article : Google Scholar : PubMed/NCBI

52 

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar : PubMed/NCBI

53 

Ihan A, Tepez B, Gubina M, Malovrh T and Kopitar A: Diminished interferon-gamma production in gastric mucosa T lymphocytes after H. pylori eradication in duodenal ulcer patients. Hepatogastroenterology. 46:1740–1745. 1999.PubMed/NCBI

54 

Kim MJ, Je Y, Chun J, Youn YH, Park H, Nahm JH and Kim JH: Helicobacter pylori eradication is associated with a reduced risk of metachronous gastric neoplasia by restoring immune function in the gastric mucosa. Helicobacter. 30:e700302025. View Article : Google Scholar : PubMed/NCBI

55 

Fu Y, Tong J, Zhu M, Xu L, Huang F, Zhang Y, Wang X, Wang Z, Zhang J, Lv J, et al: Helicobacter pylori-induced inflammatory cancer transformation microenvironment drives gastric carcinogenesis. Cell Mol Gastroenterol Hepatol. 20:1017572026. View Article : Google Scholar : PubMed/NCBI

56 

Huang KK, Ma H, Chong RHH, Uchihara T, Lian BSX, Zhu F, Sheng T, Srivastava S, Tay ST, Sundar R, et al: Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression. Cancer Cell. 41:2019–2037.e8. 2023. View Article : Google Scholar : PubMed/NCBI

57 

Kim H, Kim J, Jeong IH, Park E, Yoo M, Yoon S, Lee D, Myung J, Choi E, Goldenring JR and Jang B: Hybrid identity and distinct methylation profiles of incomplete intestinal metaplasia in the stomach. Gut. 75:10–23. 2026. View Article : Google Scholar

58 

Curtius K, Wright NA and Graham TA: An evolutionary perspective on field cancerization. Nat Rev Cancer. 18:19–32. 2018. View Article : Google Scholar : PubMed/NCBI

59 

Collins GS, Reitsma JB, Altman DG and Moons KGM: Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Ann Intern Med. 162:55–63. 2015. View Article : Google Scholar : PubMed/NCBI

60 

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, : REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 93:387–391. 2005. View Article : Google Scholar : PubMed/NCBI

61 

Hu W, Chen ZM, Wang Y, Yang C, Wu ZY, You LJ, Zhai ZY, Huang ZY, Zhou P, Huang SL, et al: Single-cell RNA sequencing dissects the immunosuppressive signatures in Helicobacter pylori-infected human gastric ecosystem. Nat Commun. 16:39032025. View Article : Google Scholar : PubMed/NCBI

62 

Huang RJ, Wichmann IA, Su A, Sathe A, Shum MV, Grimes SM, Meka R, Almeda A, Bai X, Shen J, et al: A spatial transcriptomic signature of 26 genes resolved at single-cell resolution characterizes high-risk gastric cancer precursors. NPJ Precis Oncol. 9:522025. View Article : Google Scholar : PubMed/NCBI

63 

Koch MRA, Gong R, Friedrich V, Engelsberger V, Kretschmer L, Wanisch A, Jarosch S, Ralser A, Lugen B, Quante M, et al: CagA-specific gastric CD8+ tissue-resident T cells control Helicobacter pylori during the early infection phase. Gastroenterology. 164:550–566. 2023. View Article : Google Scholar : PubMed/NCBI

64 

Law AMK, Chen J, Colino-Sanguino Y, Rodriguez de la Fuente L, Fang G, Grimes SM, Lu H, Huang RJ, Boyle ST, Venhuizen J, et al: ALTEN: A high-fidelity primary tissue-engineering platform to assess cellular responses ex vivo. Adv Sci (Weinh). 9:e21033322022. View Article : Google Scholar : PubMed/NCBI

65 

Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J and Mallett S; PROBAST Group†, : PROBAST: A tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 170:51–58. 2019. View Article : Google Scholar : PubMed/NCBI

66 

Vickers AJ and Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making. 26:565–574. 2006. View Article : Google Scholar : PubMed/NCBI

67 

Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, et al: Defining trained immunity and its role in health and disease. Nat Rev Immunol. 20:375–388. 2020. View Article : Google Scholar : PubMed/NCBI

68 

Szabo PA, Miron M and Farber DL: Location, location, location: Tissue resident memory T cells in mice and humans. Sci Immunol. 4:eaas96732019. View Article : Google Scholar : PubMed/NCBI

69 

Sorini C, Tripathi KP, Wu S, Higdon SM, Wang J, Cheng L, Banerjee S, Reinhardt A, Kreslavsky T, Thorell A, et al: Metagenomic and single-cell RNA-Seq survey of the Helicobacter pylori-infected stomach in asymptomatic individuals. JCI Insight. 8:e1610422023. View Article : Google Scholar : PubMed/NCBI

70 

Li N, Chen S, Xu X, Wang H, Zheng P, Fei X, Ke H, Lei Y, Zhou Y, Yang X, et al: Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with Helicobacter pylori. J Adv Res. 74:471–491. 2025. View Article : Google Scholar : PubMed/NCBI

71 

Nowicki-Osuch K, Zhuang L, Cheung TS, Black E, Masqué-Soler N, Devonshire G, Redmond A, Freeman A, di Pietro M, Pilonis N, et al: Single-cell RNA sequencing unifies developmental programs of esophageal and gastric intestinal metaplasia. Cancer Discov. 13:1346–1363. 2023. View Article : Google Scholar : PubMed/NCBI

72 

Kim J, Park C, Kim KH, Kim EH, Kim H, Woo JK, Seong JK, Nam KT, Lee YC and Cho SY: Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity. NPJ Precis Oncol. 6:92022. View Article : Google Scholar : PubMed/NCBI

73 

Chen X, Jiang X, Wang S, Xia J, Wang W, Fu X, Yukun P, Liu Z, Li Y, Zhang M and Ding Y: Integrated single-cell and spatial transcriptomics reveal the differentiation drivers of gastric epithelial lineage progression. Front Immunol. 17:17128302026. View Article : Google Scholar : PubMed/NCBI

74 

Ye Y, Gong X, Liu S, Hu N, Zhang H, Fei X, Huang A, Fan W, Chen Z, Wang H, et al: A single-cell multi-omics atlas defines the cellular and molecular landscape of gastric intestinal metaplasia. J Transl Med. 24:7242026. View Article : Google Scholar : PubMed/NCBI

75 

Yin H, Zhang H, Zheng S, Guo R, Wen J, Liu M, Li A, Zhao M, Yuan Y and Gong Y: Dissecting the differentiation origins of intestinal metaplasia and early intestinal-type gastric cancer in gastric antrum by single-cell RNA profiling. NPJ Precis Oncol. 10:1672026. View Article : Google Scholar : PubMed/NCBI

76 

Tsai CJ, Herrera-Goepfert R, Tibshirani RJ, Yang S, Mohar A, Guarner J and Parsonnet J: Changes of gene expression in gastric preneoplasia following Helicobacter pylori eradication therapy. Cancer Epidemiol Biomarkers Prev. 15:272–280. 2006. View Article : Google Scholar : PubMed/NCBI

77 

Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, Yasuda T, Koh V, Huang KK, Tay ST, et al: Single-cell atlas of lineage states, tumor microenvironment and subtype-specific expression programs in gastric cancer. Cancer Discov. 12:670–691. 2022. View Article : Google Scholar : PubMed/NCBI

78 

Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, Wu J, Liu B, Ying X and Liu Y: Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut. 70:464–475. 2021. View Article : Google Scholar : PubMed/NCBI

79 

Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al: Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity. 41:14–20. 2014. View Article : Google Scholar : PubMed/NCBI

80 

Su Z, He Y, You L, Chen J, Zhang G and Liu Z: SPP1+ macrophages and FAP+ fibroblasts promote the progression of pMMR gastric cancer. Sci Rep. 14:262212024. View Article : Google Scholar : PubMed/NCBI

81 

Qiu L, Zhao X, Yao S, Fei Y, Gong Y, Zhou Z, Jiao S and Xu J: Multi-omics analyses reveal interactions between GREM1+ fibroblasts and SPP1+ macrophages in gastric cancer. NPJ Precis Oncol. 9:1642025. View Article : Google Scholar : PubMed/NCBI

82 

Ma G, Liu X, Jiang Q, Li S, Wu Q, Liang B, Sun F, Gu C, Liao W, Zhang Z, et al: Identification of a stromal immunosuppressive barrier orchestrated by SPP1+/C1QC+ macrophages and CD8+ exhausted T cells driving gastric cancer immunotherapy resistance. Front Immunol. 16:16185912025. View Article : Google Scholar : PubMed/NCBI

83 

Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM and Lundin BS: Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun. 71:1755–1762. 2003. View Article : Google Scholar : PubMed/NCBI

84 

Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M, Tasca E, Azzurri A, D'Elios MM, DelPrete G and de Bernard M: The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 116:1092–1101. 2006. View Article : Google Scholar : PubMed/NCBI

85 

Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP, Reindl W, Dossumbekova A, Friedrich M, Saur D, et al: CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology. 131:525–537. 2006. View Article : Google Scholar : PubMed/NCBI

86 

Kao JY, Zhang M, Miller MJ, Mills JC, Wang B, Liu M, Eaton KA, Zou W, Berndt BE, Cole TS, et al: Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology. 138:1046–1054. 2010. View Article : Google Scholar : PubMed/NCBI

87 

Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, Gerhard M, Taube C and Müller A: Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA. 110:3047–3052. 2013. View Article : Google Scholar : PubMed/NCBI

88 

Hitzler I, Sayi A, Kohler E, Engler DB, Koch KN, Hardt WD and Müller A: Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1β and IL-18. J Immunol. 188:3594–3602. 2012. View Article : Google Scholar : PubMed/NCBI

89 

Caruso R, Pallone F and Monteleone G: Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol. 13:5547–5551. 2007. View Article : Google Scholar : PubMed/NCBI

90 

Xia T, Zhang Z, Xie J, Yuan H, Ren Y, Xu Y, Ning J, Li B and Wu C: Gastric mucosal CD8+TRM cells are recruited through CXCR5-CXCL13 axis in Helicobacter pylori infected subjects. Cytokine. 190:1569042025. View Article : Google Scholar : PubMed/NCBI

91 

Gong R, Huang B, Ralser A, Friedrich V, Mibus C, Engelsberger V, Koch MRA, Skerhut M, Giese T, Andrä I, et al: CagA-dependent Hobit+ gastric tissue-resident memory T cells confer full protection from Helicobacter pylori reinfection. Gut. 74:1792–1803. 2025. View Article : Google Scholar : PubMed/NCBI

92 

Bockerstett KA, Lewis SA, Noto CN, Ford EL, Saenz JB, Jackson NM, Ahn TH, Mills JC and DiPaolo RJ: Single- cell transcriptional analyses identify lineage-specific epithelial responses to inflammation and metaplastic development in the gastric corpus. Gastroenterology. 159:2116–2129.e4. 2020. View Article : Google Scholar : PubMed/NCBI

93 

Petersen CP, Mills JC and Goldenring JR: Murine models of gastric corpus preneoplasia. Cell Mol Gastroenterol Hepatol. 3:11–26. 2016. View Article : Google Scholar : PubMed/NCBI

94 

Nam KT, Lee HJ, Sousa JF, Weis VG, O'Neal RL, Finke PE, Romero-Gallo J, Shi G, Mills JC, Peek RM Jr, et al: Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology. 139:2028–2037.e9. 2010. View Article : Google Scholar : PubMed/NCBI

95 

Goldenring JR and Nam KT: Oxyntic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci. 96:117–131. 2010. View Article : Google Scholar : PubMed/NCBI

96 

Mills JC and Goldenring JR: Metaplasia in the stomach arises from gastric chief cells. Cell Mol Gastroenterol Hepatol. 4:85–88. 2017. View Article : Google Scholar : PubMed/NCBI

97 

Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI

98 

Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI

99 

Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI

100 

Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI

101 

Banks M, Graham D, Jansen M, Gotoda T, Coda S, di Pietro M, Uedo N, Bhandari P, Pritchard DM, Kuipers EJ, et al: British society of gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 68:1545–1575. 2019. View Article : Google Scholar : PubMed/NCBI

102 

Sung JK: Diagnosis and management of gastric dysplasia. Korean J Intern Med. 31:201–209. 2016. View Article : Google Scholar : PubMed/NCBI

103 

Song L and Yu QY: Stratified management of residual gastric cancer risk after Helicobacter pylori eradication. Front Microbiol. 17:17794902026. View Article : Google Scholar : PubMed/NCBI

104 

Ding T, Hu W, Qi X, Zhang Y and Wang H: Advances in Helicobacter pylori-mediated oncogenic signaling pathways in gastric cancer: From pathological evolution to clinical application prospects (Review). Oncol Lett. 32:4082026. View Article : Google Scholar : PubMed/NCBI

105 

Guan Z, Han L, Chen B, Ma Y, Ni Q, Wang Z, Yang J and Liu Z: Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review). Oncol Lett. 31:1082026. View Article : Google Scholar : PubMed/NCBI

106 

Moncada R, Barkley D, Wagner F, Chiodin M, Devlin JC, Baron M, Hajdu CH, Simeone DM and Yanai I: Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol. 38:333–342. 2020. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Chen J, Tang B and Zhou L: Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review). Oncol Lett 33: 5, 2027.
APA
Chen, J., Tang, B., & Zhou, L. (2027). Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review). Oncology Letters, 33, 5. https://doi.org/10.3892/ol.2026.15940
MLA
Chen, J., Tang, B., Zhou, L."Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review)". Oncology Letters 33.1 (2027): 5.
Chicago
Chen, J., Tang, B., Zhou, L."Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review)". Oncology Letters 33, no. 1 (2027): 5. https://doi.org/10.3892/ol.2026.15940
Copy and paste a formatted citation
x
Spandidos Publications style
Chen J, Tang B and Zhou L: Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review). Oncol Lett 33: 5, 2027.
APA
Chen, J., Tang, B., & Zhou, L. (2027). Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review). Oncology Letters, 33, 5. https://doi.org/10.3892/ol.2026.15940
MLA
Chen, J., Tang, B., Zhou, L."Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review)". Oncology Letters 33.1 (2027): 5.
Chicago
Chen, J., Tang, B., Zhou, L."Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review)". Oncology Letters 33, no. 1 (2027): 5. https://doi.org/10.3892/ol.2026.15940
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team